Sera Prognostics, Inc. Class A

Stage 1 · Basing · week 13

As of Oct 22, 2026, Sera Prognostics is in Stage 1, the basing phase, now in week 13 (since Jul 27, 2026). It closed at $2.04, 45.6% below its 52-week high and below its 200-day average, which is falling.

$2.04

+0.49% today

$80.5M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Basing, not in an uptrend yet

Setup score

—

Momentum

Steady

Edge

—

Is SERA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 22w

S4 27w

S1 14w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S3 3w → S4 12w → S1 4w → S2 22w → S3 11w → S4 4w → S1 5w → S4 3w → S1 2w → S4 4w → S1 5w → S4 27w → S1 14w → S2 3w → S3 2w → S2 9w → S3 4w → S4 13w → S1 2w → S4 4w → S1 13w current

Total tracked: 165 weeks across 21 stage runs.

SERA among Medical Devices80th of 141 by relative strength

All 141 →

Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	TXG10x Genomics, Inc.	Stage 2 · wk 48	99	−7.8%
2	RCELAvita Medical, Inc.	Stage 2 · wk 13	98	+40.8%
3	BFLYButterfly Network, Inc. Class A	Stage 2 · wk 26	98	−26.0%
4	HAEHaemonetics Corporation	Stage 2 · wk 17	96	+8.7%
5	GKOSGlaukos Corporation	Stage 2 · wk 25	96	+15.1%
6	AXGNAxogen, Inc.	Stage 3 · wk 2	95	−15.3%
7	NEOGNeogen Corporation	Stage 2 · wk 14	95	−11.7%
8	BVSBioventus Inc. Class A	Stage 2 · wk 15	95	+10.5%
…80	SERASera Prognostics, Inc. Class A	Stage 1 · wk 13	28	−1.0%

vs 52W High

-45.6%

$1.59 lo$3.75 hi

45.6% below 52W high

Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.

Stage Maturity

Week 13

1w13w26w

Week 13, base building

How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.

vs 200 DMA

-6.2%

200 DMA: $2.18 · sloping down

Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.

Rel Volume

1.61x

vs 50-day avg

Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.

Trend Health

→

Short-term trend flat

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-1.0%

-0.5%

-3.8%

YTD

-32.0%

-39.3%

Scan Membership

Breakout Watch

Latest: 2023-12-27

2 appearances in last 60 days. First seen: 2023-02-27.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S1

Wk 13 · Vol 1.61x

2026-10-21S1

Wk 13 · Vol 1.24x

2026-10-20S1

Wk 13 · Vol 1.59x

2026-10-19S1

Wk 12 · Vol 0.26x

2026-10-16S1

Wk 12 · Vol 0.17x

2026-10-15S1

Wk 12 · Vol 0.61x

2026-10-14S1

Wk 12 · Vol 0.25x

2026-10-13S1

Wk 12 · Vol 0.20x

2026-10-12S1

Wk 11 · Vol 0.57x

2026-10-09S1

Wk 11 · Vol 0.25x

2026-10-08S1

Wk 11 · Vol 0.53x

2026-10-07S1

Wk 11 · Vol 0.03x

Moving averages & range

50 DMA

$2.05

200 DMA

$2.18

52W High

$3.75

52W Low

$1.59

5D Low

$2.03

Resistance levels (recent highs)

20d High

$2.09

60d High

$2.18

120d High

$2.29

250d High

$3.75

Next resistance

+2.5%

to 20d High

ROE

-45.0%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 1.4

Sera Prognostics: quick answers

What stage is Sera Prognostics in?

As of Oct 22, 2026, Sera Prognostics (SERA) is in Stage 1, the basing phase. It entered Stage 1 on Jul 27, 2026 and is in week 13. What the four stages mean

Is Sera Prognostics in an uptrend?

Not yet. Sera Prognostics is in Stage 1, a base that can come before an uptrend. It trades 6.2% below its 200-day average, which is falling.

How far is Sera Prognostics from its 52-week high?

Sera Prognostics closed at $2.04 on Oct 22, 2026, 45.6% below its 52-week high of $3.75. Its 52-week low is $1.59.

How has Sera Prognostics performed over the past year?

As of Oct 22, 2026, Sera Prognostics is down 39.3% over the past year and down 32.0% so far in 2026.

Which sector and industry is Sera Prognostics in?

Sera Prognostics is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.